Rallybio to become oncology player Avenzo, backed by $215M placement
What's the deal? Rallybio will merge with Avenzo Therapeutics and rename itself Avenzo, trading on the Nasdaq Capital Market under the symbol "AVZO." Ahead of closing, Rallybio is running a one-for-two reverse stock split, cutting its share count from about 5.6 million to 2.8 million.
Why now? Stockholders approved the merger and a reverse split range of one-for-two to one-for-nine at the November 4, 2026 annual meeting. Rallybio and Avenzo jointly chose the one-for-two ratio, with the split set to take effect at 12:01 EST on November 20, 2026, just before the merger completes.
What's the endgame? The transaction turns Rallybio into Avenzo, shifting the business into oncology. The deal is backed by a $215 million private placement and a planned $83.6 million cash distribution to Rallybio holders.
What changes for shareholders? By itself, the split does not alter the merger's economics or any holder's percentage stake. It combines every two shares into one, with cash paid in lieu of fractional shares.
The signal: The real story is the pivot into oncology and its financing, not the share adjustment. The split is a closing mechanic that does not, on its own, add shareholder value.
Read more: finance.yahoo.com
Image credit: serge.zykov
